Who Holds the Viagra Patent and When Did Pfizer Lose It?

The viagra patent history begins with Pfizer's discovery that sildenafil citrate — originally developed as a cardiovascular drug — produced erections as a side effect during clinical trials. Pfizer filed the key patent for sildenafil's use in treating ED in 1996 and received FDA approval for Viagra in March 1998. The patent landscape has changed significantly since then, opening the market to generic sildenafil that is now available at a fraction of the original price.

The Original Patent and Its Expiry

Pfizer's compound patent on sildenafil (US Patent 5,250,534) covered the molecule itself, while its use patent (US Patent 6,469,012) specifically covered sildenafil's application for ED treatment. In the United States, the compound patent expired in 2012, but the use patent was upheld until 2020. In the UK and Europe, Pfizer's supplementary protection certificate (SPC) for Viagra expired in June 2013, allowing generic manufacturers to enter the market.

The result was a dramatic price collapse: branded Viagra that cost £8–10 per tablet dropped to £1–3 per tablet for generic sildenafil within months of patent expiry.

What Generic Sildenafil Means for Patients

Generic sildenafil is bioequivalent to branded Viagra — it contains the same active ingredient at the same dose and is subject to the same regulatory standards. The MHRA requires generic manufacturers to demonstrate equivalent bioavailability before licensing. There is no clinically meaningful difference between branded and generic sildenafil in terms of efficacy or safety.

The availability of affordable generics has also enabled over-the-counter access: Viagra Connect (sildenafil 50 mg sold without prescription) became available in UK pharmacies in 2018. For guidance on purchasing safely, see how to buy Viagra online without a prescription.

Patent Challenges and Litigation

Several generic manufacturers challenged Pfizer's patents before their scheduled expiry, particularly the use patent covering ED treatment. Teva Pharmaceuticals successfully challenged the use patent in certain jurisdictions, accelerating generic entry. Pfizer settled with several generic manufacturers, granting early market access in exchange for licensing fees — a common pharmaceutical patent strategy.

The patent disputes also affected related products. Counterfeit operations and unregulated "herbal" alternatives proliferated during the period of high branded Viagra prices. For a review of what these products actually contain and the safety risks they pose, see Herbal Viagra: Ingredients, Safety, and What to Know.

For more on ED medication options, pricing, and how different PDE5 inhibitors compare, visit the Erectile Dysfunction hub page.